242 filings
Page 5 of 13
DEFA14A
0dsmee999
1 May 23
Additional proxy soliciting materials
4:07pm
424B5
81m991j5o90lk
27 Apr 23
Prospectus supplement for primary offering
4:44pm
424B5
17ki4ozqw5j5
26 Apr 23
Prospectus supplement for primary offering
8:23am
8-K
50110
24 Apr 23
Regulation FD Disclosure
8:19am
4
o6g2 i76xzv7w
18 Apr 23
IN8BIO / Kate Rochlin ownership change
5:06pm
4
3siy c1hre
18 Apr 23
IN8BIO / Patrick McCall ownership change
5:04pm
4
8bfu7u8k9o wr4cs
18 Apr 23
IN8BIO / Lawrence Lamb ownership change
5:02pm
4
nx83kmw bh10q
18 Apr 23
IN8BIO / William Tai-Wei Ho ownership change
5:01pm
4
98gl2l5xq68zg0
18 Apr 23
IN8BIO / Trishna Goswami ownership change
5:00pm
8-K
4rd mpflayy7l8wl
17 Apr 23
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
4:02pm
8-K
224y6m865 petwr56n
30 Mar 23
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
4:20pm
8-K
rc84nmar1
10 Mar 23
Regulation FD Disclosure
9:03pm
8-K
hdlru41066t9ih3i63y
23 Feb 23
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
7:08am
8-K
jp7dq6kvx up
5 Jan 23
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
7:08am
4
ldmynx cno5
13 Dec 22
IN8BIO / Leslie W. Kreis ownership change
7:01am
4
ixv97mm wo0l1r
13 Dec 22
IN8BIO / Aaron G.L. Fletcher ownership change
7:00am
8-K
gglumy m1
12 Dec 22
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
7:53am
8-K
rxdm5q
8 Dec 22
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
7:10am